see attached

Unit 14 Assignment Clinical Journal Reflection 900w-4-references. Due 4-10-25.

· This is the last journal entry, please reflect on the previous 6 entries that are below and evaluate your claims in a reflective practice over the course of the term.

Use the appropriate APA formatting with a minimum of 4 references to support your work.

All components must be discussed to receive full credit as complete.

Unit 3 Clinical Journal Reflection: Maternal Mental Health

Introduction

Psychiatric Mental Health Nurse Practitioners (PMHNPS) are in the process of professional development whereby one of the fundamental components is selfreflection. It allows providers to assess their emotional health, identify personal triggers, and track how their thoughts and actions impact their practice (Fritz et al., 2024). As a PMHNP, it is important to understand how you respond to different cases to ensure you provide high quality patient care while maintaining professional boundaries so that a conclusion like this can be avoided. Maternal mental health, a topic considered deeply personal and professional for me, is the subject of this reflective journal. It examines an advocacy group, the Maternal Mental Health Leadership Alliance (MMHLA), to determine its value in addressing issues associated with maternal mental health.

Passion for Maternal Mental Health

Mental health professionals are focusing on maternal mental health as this is concerned with how psychologically healthy the women are during pregnancy or childbirth or the postpartum period. This matter affects me on a personal level, because of its extensive implications on mothers and their children. Postpartum depression, postpartum anxiety, and postpartum psychosis are often underdiagnosed and undertreated maternal mental health disorders. Chauhan and Potdar (2022) particularly highlight that 20% of women can experience substantial mental health issues during pregnancy or after delivery, leading to poor quality of life and children’s developmental outcomes.

As a clinician and registered nurse, I have experienced first hand its impact on patients and their families. Women suffering from untreated mental health conditions often find it challenging to establish a bond with their children (or infant), to take care of them, and retain a balanced lifestyle. Solving these problems results in healthier family dynamics and mitigates the potential for the intergenerational transmission of poor mental health. I'm dedicated to becoming an advocate to know maternal mental health awareness and intervention because of this passion.

Advocacy Group: Maternal Mental Health Leadership Alliance (MMHLA)

The Maternal Mental Health Leadership Alliance (MMHLA) is an organization committed to enhancing maternal mental health awareness, decreasing stigma, and promoting and advocating for policies that support the mental health needs of mothers. Furthermore, MMHLA’s mission closely aligns with my future goals as a PMHNP, given its shared focus on implementing a bottom up approach that includes greater collaboration, education, and policy change to advance maternal mental health.

Importance of MMHLA

MMHLA’s work is crucial because it connects the dots between healthcare providers, policymakers, and community stakeholders. The group’s campaigning involves securing increased funding for maternal mental health programs, increasing access to care, and improving the provision of mental health services for mothers. For example, their passings have led to federal legislation like the Maternal Health Quality Improvement Act which was created in order to improve maternal health outcomes, utilizing evidence based practices (MMHLA, n.d.).

By joining MMHLA you will connect with a network of like minded professionals working actively to improve maternal mental health. Resources like webinars, toolkits, policy briefs that the organization has shared give a glimpse into best practices, new tools, and innovative approaches to care. Through collaborating with MMHLA, I can amplify my impact as a PMHNP and contribute to systemic changes that help mothers and families across the entire country.

The site serves (https://www.mmhla.org/) as a hub for information, advocacy tools, and community engagement. This showcases the organization’s successes to date and its current efforts, reinforcing its presence in the maternal mental health landscape.

Self-Reflection on Emotional Health and Triggers

For a PMHNP, emotional health is essential to provide compassionate care. Through reflective practice, I was able to identify the triggers that could affect my ability to be objective and empathetic. Often, maternal mental health cases cause intense emotions, as they involve some vulnerable populations as well as complex social factors.

Seeing the systemic barriers to accessing mental health care is one of my primary triggers. According to Wang (2022), socioeconomic factors, cultural stigma, and limited provider availability are the main barriers for maternal mental health care access. While working with underserved populations, these challenges can bring frustration and helplessness with it.

In order to manage these emotions, I have shifted my mindset towards being solution focused, and leveraging resources available to me to help patients. It could connect mothers with local support groups or telehealth services to address some of these barriers (Wang, 2022). I also practice self care through mindfulness and peer supervision to manage stress and maintain professional boundaries.

Types of Cases and Referral Preferences

Through reflective practice, I discover which cases of maternal mental health really speak to me. They include cases of postpartum depression and anxiety because they provide us the opportunity to make a valuable change in the lives of the patients (Fritz et al., 2024). I understand, however, that there are specific cases where, due to the severity of postpartum psychosis or coexisting substance use disorders, specialized expertise beyond my practice scope may be needed.

Patients are referred to the specialists or interdisciplinary teams to receive comprehensive care. For instance, in complex cases, collaboration with psychiatrists, social workers, and addiction specialists may improve treatment outcomes. This supports care coordination principles, also highlighting the value of teamwork in addressing maternal mental health issues.

Personal Behaviors, Thoughts, and Decisions

As a PMHNP, my behaviors, thoughts, and decisions have a substantial impact on patient care outcomes. Reflective practice is a way for me to assess areas where I need to grow and improve, including increasing my communication skills, learning how to manage countertransference, and staying up to date on emerging research regarding maternal mental health.

Reflecting about it, I learned that cultural competence is of utmost importance in maternal mental health care. As such Mother who are culturally diverse do not have the same needs than Mother of another culture (Fritz et al., 2024). Preventing bad behaviors requires preventiveness, and if I want to be proactive about understanding patients’ cultural values and preferences, I can develop trust and establish a therapeutic alliance that will lead to a favorable outcome.

Additionally, proactive reflective practice does prompt the individual to stay current with existing, evidence based interventions for maternal mental health. The paper of Voit et al. (2022) makes a great point on how maternal mental health is related to poor birth outcomes and highlight the need for early intervention as well as for comprehensive care. Integrating these insights into my own practice allows me to care for mothers and their families in a more effective and compassionate way.

Advocacy and Professional Growth

Professional growth in PMHNPs is core advocacy. Participating in organizations such as MMHLA allows me to be part of change in a system that can improve maternal mental health outcomes. This same advocacy work also helps me to understand the policy making and implementation process, which are important to address the social determinant of health affecting maternal mental health.

Through my reflective practice, I also appreciate how this interrelation of mental health and social justice. A comprehensive and multileveled solution to address maternal mental health challenges also includes policy advocacy; community engagement; and direct clinical care. But this holistic view of personal development pushed me to reach to the professional goals and keep learning and improving.

Conclusion

Maternal mental health is a very personal and professionally relevant issue, supporting the need for reflective practice for PMHNPs. I will increase my effectiveness as a provider by exploring my passion for this area, engaging in advocacy groups like MMHLA and reflecting on what triggers emotional health, decision-making processes. I will continue to advocate and pursue self-reflection to influence the lives of mothers and their families and the mental health and wellbeing of future generations.

References

Chauhan, A., & Potdar, J. (2022). Maternal mental health during pregnancy: a critical review.  Cureus,  14(10). https://doi.org/10.7759/cureus.30656

Fritz, L., Nachreiner, L., Pinske, J., & Speer, M. (2024). 2024-03: Addressing Mental Health Needs of Mothers in Minnesota. https://cornerstone.lib.mnsu.edu/msw-student-policy-advocacy-briefs/55

Voit, F. A., Kajantie, E., Lemola, S., Räikkönen, K., Wolke, D., & Schnitzlein, D. D. (2022). Maternal mental health and adverse birth outcomes.  Plos one,  17(8), e0272210. https://doi.org/10.1371/journal.pone.0272210

Wang, S. R. (2022).  Barriers and Facilitators to Maternal Mental Health Care Access: A Qualitative Analysis. University of Washington. https://www.proquest.com/openview/0c7da35bfb61e35380acad926f902388/1?pq-origsite=gscholar&cbl=18750&diss=y

Reflective Journal: Self-Reflection as a PMHNP Provider

Introduction

As a future Psychiatric Mental Health Nurse Practitioner (PMHNP), self-reflection is crucial because it helps understand how personal biases, treatment preferences as well as external influences affect clinical practice. Research shows that sleep issues result from anxiety and behavioral disorders as well as medical conditions like sleep apnea. Having begun my own professional development centered around assessing and treating sleep disorders, such as Cognitive Behavioral Therapy for Insomnia (CBT-I) and guidelines based on evidence, I am evaluating best practices as doing so. The purposes of this reflection will be to discuss some important points when dealing with patient sleep disorder management, such as drug treatments versus behavioral interventions, and whether these can be integrated into a holistic approach of patient care in achieving improved outcomes.

Children and Sleep Issues

The belief that children do not suffer from sleep issues is false. Blaming an increase in sugar intake for insomnia in children is also false. Some potential causes that might be related to sleep disorder in children include anxiety, behavioral disorder, and medical issues like obstructive sleep apnea (Bijwadia, 2022). As future PMHNP it is imperative that we address the underline cause of insomnia in an effort to increase patient outcome. It is important to understand that diet influences sleep to a great extent. However, it does not affect sleep in isolation. Moreover, sleep quality, irregular schedules, and external conditions contribute to sleep problems in children as well.

Classification of Sleep Disorders

Thus, the idea that there are only three types of sleep disorders, including narcolepsy, sleep apnea, and stress-induce insomnia, is very limited. According to the AASM classification, sleep disorders can be grouped into several subtypes such as insomnia disorders, circadian rhythm sleep disorders, and parasomnias (Bijwadia, 2022). Such conditions require comprehensive assessment in order to achieve effective diagnosis and treatment. For instance, there can be various causes for insomnia, including anxiety, depression, and lifestyle, thus necessitating a complex intervention.

Over-the-Counter Sleep Aids vs. Prescription Sleep Aids

OTC sleep aids seem to be safer than the prescription counterparts, but that is not always the case. Some OTC sleep aids/Remedies like antihistamines causes tolerance and may result in daytime drowsiness. Essentially, CBT-I and behavioral interventions remain preferable to pharmacological treatments for insomnia (Edinger et al., 2021). It is important for prescription sleep aids given their side effects to be given based on the patient’s circumstances and health history. Secondly, many OTC sleep aids have not been tested for long-term use and therefore requires that patients consult their doctors before taking them.

Menopause and Sleep Patterns

Menopause does affect sleep; therefore, the statement is false that it does not affect sleep. The hormonal changes that occur during menopause play a vital role in insomnia and sleep disturbance. Research shows that the reduction in estrogen levels contributes to a higher number of awakenings during the night and reduced sleep quality (Krystal, Prather, & Ashbrook, 2019). A long-term integration of management approaches like hormone replacement therapy and behavior therapy may be needed for a particular candidate. Other contributing factors include increased risk for restless legs syndrome, sleep disturbances and mood swings.

Use of Benzodiazepines as First-Line Treatment

It is important not to prescribe benzodiazepines as a first-line treatment for sleep disorders because they can lead to dependence, and the impairment of cognition. CBT-I is the first-line treatment, and the use of non-benzodiazepine hypnotics is recommended, if medication is needed (Mysliwiec et al., 2020). It is recommended that benzodiazepines should only be used in circumstances where indicated for short-term use and only under the direction of a healthcare practitioner. It has been associated with adverse side effects, such as cognitive dysfunction, withdrawal syndrome, and raising the likelihood of falls in elderly patients, making them less beneficial for the treatment of chronic insomnia.

Best Practices for Insomnia Assessment and Treatment

Insomnia should be diagnosed based on sleep diary, sleep diary; and assessment of other factors which include food habits, occupational and psychosocial factors, and medical condition. Official questionnaires and tools like the Insomnia Severity Index can also be utilized to facilitate diagnosis (Edinger et al., 2021). Cognitive-behavioral therapy for insomnia (CBT-I) should be preferred, as it has been shown to have consistent effectiveness in the long term.

Recommended Treatment Guideline

Among the most popular guidelines for treating insomnia, is the 2019 United States Department of Veteran Affairs, Department of Defence Clinical Practice Guidelines. These guidelines support behavioral therapies as initial treatment approaches and offer a systematic approach to pharmacologic management only if needed (Mysliwiec et al., 2020). Adopting the best practices of pharmacotherapy refers to the efficient and effective treatment of patients to reduce the risk factors associated with the use of medicines. These guidelines also respect the role of mental and physical health disorders in contributing to sleep dysfunction.

Conclusion

Finally, in an attempt to become a Psychiatric Mental Health Nurse Practitioner (PMHNP), self-reflection will be one of the most important aspects of my career as I learn how to practice clinical. I will be able to self-reflect and determine where my own personal biases, triggers, and treatment preferences may be negatively affecting my judgment. This will assist me in being aware of how these factors may contribute to my interactions with patients and their treatment plans. Additionally, a complete comprehension of sleep problems and their management is essential to be able to give appropriate care. I will have the knowledge of the latest research; evidence based interventions and will make informed decisions based on health and well-being of my patients. Application of psychological, behavioral, and medical practices into treatment plans allows me to develop a holistic and patient centered approach in delivering care. This interdisciplinary approach to patients with sleep disorders achieves patient satisfaction, improves mental health and quality of life. I will continue to improve my expertise in order to continue to provide the best care in research and professional integrity.

References

Bijwadia, J. (2022). Current Classification of Sleep Disorders. In  Dental Sleep Medicine: A Clinical Guide (pp. 71-101). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-10646-0_3

Edinger, J. D., Arnedt, J. T., Bertisch, S. M., Carney, C. E., Harrington, J. J., Lichstein, K. L., ... & Martin, J. L. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline.  Journal of Clinical Sleep Medicine,  17(2), 255-262. https://doi.org/10.5664/jcsm.8986

Krystal, A. D., Prather, A. A., & Ashbrook, L. H. (2019). The assessment and management of insomnia: an update.  World Psychiatry,  18(3), 337-352. https://doi.org/10.1002/wps.20674

Mysliwiec, V., Martin, J. L., Ulmer, C. S., Chowdhuri, S., Brock, M. S., Spevak, C., & Sall, J. (2020). The management of chronic insomnia disorder and obstructive sleep apnea: synopsis of the 2019 US Department of Veterans Affairs and US Department of Defense clinical practice guidelines.  Annals of internal medicine. https://doi.org/10.7326/M19-3575

Comparison of Methadone and Buprenorphine

Methadone and buprenorphine are both opioid agonist treatments (OAT) that are commonly applied within the treatment of Opioid use disorder (OUD). They are both used for similar purpose but they work in different ways, have different advantages and disadvantages.

Mechanism of Action

Methadone is an opioid analgesic in the opium alkaloid class of drugs that mimics the effects of endogenous opioids by binding to the mu-opioid receptors in the brain without causing a rapid rise or high, thus making it useful in the management of opiate addiction as it helps prevent withdrawal symptoms and cravings (Degenhardt et al., 2023). Despite the fact that methadone is a full agonist, it can be much more dangerous in terms of its potential to induce respiratory depression and overdose if used inappropriately.

Buprenorphine however, is an opioid partial agonist. It interacts with the same receptors as methadone but causes less activation and the side effects do not increase even if a large amount is taken thus makes it impossible to overdose (Degenhardt et al., 2023). In addition, buprenorphine interacts well with opioid receptors and is effective in preventing the use of other opioids and consequently a relapse.

Pros and Cons

Methadone use has been firmly established as a viable solution for opioid dependence and retention in the treatment programs (Klimas et al., 2021). Despite this, it can only be obtained from special clinics due to its potential for misuse, leading to overdosing and thus restricting its availability. Methadone patients also experience social isolation since patients are forced to report to clinics daily for their doses (Cheetham et al., 2022).

Compared to methadone, buprenorphine has the benefit of increased availability since it can be prescribed in outpatient offices (Wakeman et al., 2020). It also indicates a lower rate of respiratory depression and overdose, thus being safer for the use. It is less suitable for patients with high opioid exposure: Some patients face challenges when switching from full opioid agonists to buprenorphine since they develop withdrawal symptoms during the induction process (Degenhardt et al., 2023).

Personal Interest in Working with Substance Use Disorders

Tackling SUDs is also a critical part of the PMHNP roles since handling individuals with such disorders forms the core of most practice settings. SUDs are complex diseases that can only be managed holistically with pharmacological interventions, behavioral therapies, and supports.

Being in line to become a PMHNP, I understand the important role of the mental health practitioners in managing OUD. People experiencing opioid addiction have comorbid mental health conditions including depression, anxiety, and/or PTSD. The management of such patients should thus be comprehensive and patient-centered as well as informed by scientific knowledge and principles. Out of these, I am most interested in medication assisted treatment (MAT) alongside psychotherapy as past studies demonstrate that they are complementary and enhance the efficacy of treatment (Wakeman et al., 2020).

However, there are some challenges associated with OUD and MAT: This includes the stigma that is associated with OUD and those receiving medication for OUD. Many patients suffer from shame and stigma, and they do not want to seek help. The formulation of my goal is, As a PMHNP, I would ensure patients come to me without fear of being criticized or judged while seeking help. The knowledge of SUD treatment will enable me provide sound recommendations so as to reverse the policies that hinder access to care and the negative perception of patients that opt for opioid agonist treatment (Cheetham et al., 2022).

Importance of Substance Use Disorder Knowledge for PMHNPs

Because of the increase in opioid addiction and the need for mental health professionals who are knowledgeable about SUD detoxification and maintenance therapy, all PMHNPs need to have adequate training in these areas.

Addressing the Opioid Epidemic

The phenomenon of opioid use remains one of the biggest societal concerns given the rising rates of opioid overdose mortality. Harm reduction strategies such as medication-assisted treatment using methadone or buprenorphine has been identified to decrease mortality and enhance the quality of life in OUD clients (Thornton et al., 2023). Knowledgeable PMHNPs should be able to offer interventions and guarantee that patients receive evidence-based care in this area.

Managing Withdrawal and Preventing Relapse

Detoxification is the initial stage of managing OUD but it is not enough on its own. Especially, patients who complete detoxification without follow-up treatment remain vulnerable to relapse and therefore have an increased probability of overdosing (Wakeman et al., 2020). PMHNPs should be taught both detoxification methods and long-term management techniques for patients in long-stay care. Knowledge of methadone and buprenorphine pharmacology allows PMHNPs to determine the best treatment plan for each patient.

Overcoming Stigma and Enhancing Patients’ Experience

Stigma is one of the biggest challenges individuals face undergoing SUD treatment. Research has shown that many healthcare providers still have prejudices against patients with OUD, which distorts patients’ access to quality care (Cheetham et al., 2022).

Conclusion

Thus, methadone and buprenorphine are considered effective treatments for OUD, but they also differ in terms of their action, safety, and accessibility. Methadone is a full agonist, which needs daily clinic visits while buprenorphine is a partial agonist that can be prescribed in outpatient setting and therefore more feasible for most patients. Substance use disorder consequently cannot be overlooked in mental health practice, and as a future PMHNP, it is crucial to keep this aspect in mind. It is crucial to dispel the stigma and be knowledgeable about OUD and MAT to provide exemplary client-centered care and actively seek policy changes to benefit the patient population.

References

Cheetham, A., Picco, L., Barnett, A., Lubman, D. I., & Nielsen, S. (2022). The impact of stigma on people with opioid use disorder, opioid treatment, and policy.  Substance abuse and rehabilitation, 1-12. https://www.tandfonline.com/doi/full/10.2147/SAR.S304566

Degenhardt, L., Clark, B., Macpherson, G., Leppan, O., Nielsen, S., Zahra, E., ... & Farrell, M. (2023). Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.  The Lancet Psychiatry,  10(6), 386-402. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(23)00095-0/abstract

Klimas, J., Hamilton, M. A., Gorfinkel, L., Adam, A., Cullen, W., & Wood, E. (2021). Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials.  Systematic reviews,  10, 1-12. https://doi.org/10.1186/s13643-021-01764-9

Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., ... & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder.  JAMA network open,  3(2), e1920622-e1920622. https://doi.org/10.1001/jamanetworkopen.2019.20622

Managing Side Effects in Psychopharmacology: Risk, Benefit, and Treatment Strategies

When prescription psychiatric drugs are prescribed, effectiveness and tolerability must be balanced. These drugs may alleviate symptoms, but side effects may lower adherence and quality of life. Addressing adverse effects entails weighing the risks and benefits of continuing, switching, or augmenting medication. A full explanation of typical mental side effects and management alternatives follows.

Akathisia and Tremors

Akathisia, restlessness, and difficulty in keeping motionless are typical adverse effects of first-generation and high-potency second-generation antipsychotics. Tremors from dopamine receptor blocking may disturb patients and reduce adherence. If akathisia or tremors develop, ensure the medication can be adjusted. Reducing the dosage may help alleviate symptoms without compromising effectiveness (D’Souza & Hooten, 2023). If symptom alleviation is inadequate, moving to quetiapine or clozapine, which are lower-potency or dopamine-sparing, may help. Beta-blockers, such as propranolol, diminish restlessness without adverse effects, making them first-line therapies for akathisia. Short-term usage of benzodiazepines like clonazepam may cause drowsiness and dependency. Anticholinergics like benztropine may reduce tremors but can impair cognition and have other negative effects. The severity of symptoms and patient tolerance determine whether to stop, switch, or increase therapy.

Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia (TD)

First-generation antipsychotics often inhibit dopamine D2 receptors, causing EPS such as dystonia, rigidity, bradykinesia, and akathisia. Chronic dopamine receptor hypersensitivity from antipsychotic use causes tardive dyskinesia, a possibly irreversible movement disease (Factor, 2020). EPS is managed by reducing the dosage or switching to a lower-risk antipsychotic such as quetiapine or clozapine. Anticholinergics, such as benztropine or trihexyphenidyl, may help alleviate acute symptoms, but older individuals should use them cautiously due to potential cognitive concerns. Dopamine modulator amantadine may help. TD prevention and monitoring using the Abnormal Involuntary Movement Scale (AIMS) are crucial. Though not often possible, quitting the offender should be explored if TD develops. Changes to lower-risk agents, such as clozapine, may help. VMAT-2 inhibitors like valbenazine or deutetrabenazine may considerably lessen TD symptoms and are FDA-approved. TD's long-term effects must be weighed against continuous antipsychotic medication in the risk/benefit analysis.

Weight Gain

Second-generation antipsychotics (olanzapine, clozapine) and mood stabilizers (lithium, valproate) may cause weight gain, which is upsetting. This may harm self-esteem, adherence, and health. Before therapy, patients should learn about food, exercise, and weight management. Switching to a metabolically neutral medicine like aripiprazole, ziprasidone, or lurasidone may help with severe weight gain. Supplemental medicines like metformin may reduce weight gain if switching is not possible. GLP-1 receptor agonists, such as liraglutide and semaglutide, may help treat antipsychotic-induced weight gain (Prasad et al., 2023). The patient's reaction to therapy and desire to change lifestyle circumstances determine whether to switch or increase treatment.

Metabolic Syndrome Symptoms

Psychotropics, especially second-generation antipsychotics like olanzapine and clozapine, may cause metabolic syndrome, a cluster of disorders including obesity, hypertension, hyperlipidemia, and insulin resistance. Proactive care is needed to reduce cardiovascular disease and diabetes risk from this condition. Weight, blood pressure, fasting glucose, and cholesterol levels must be monitored regularly. Consider aripiprazole or lurasidone if metabolic metrics deteriorate. Metformin or statins may be needed if switching is not possible owing to symptom stability. Lifestyle therapies including diet advice and exercise should be promoted. For severe metabolic dysregulation, pharmacologic weight reduction medications or GLP-1 receptor agonists may be recommended. Mental health and long-term medical consequences must be considered while changing therapy.

Sexual Dysfunction

Anorgasmia, erectile dysfunction, diminished libido, and delayed ejaculation are common side effects of antidepressants (particularly SSRIs and SNRIs) and antipsychotics. Since it affects quality of life and relationships, this problem commonly causes pharmaceutical nonadherence. First, establish whether a dosage decrease is possible without affecting the therapeutic effect. If not, try a lower-risk drug. SSRI-induced sexual dysfunction may be treated with bupropion or mirtazapine, which have fewer sexual side effects. Bupropion, buspirone, or sildenafil (for males) may help if an SSRI must be maintained. Aripiprazole, a partial dopamine receptor agonist, may help antipsychotic-induced sexual dysfunction (Lipman et al., 2024). It has less sexual side effects. Symptom intensity and patient desire for medication modifications determine whether to switch or enhance therapy.

Blunted Feeling

Antipsychotics and, to a lesser degree, SSRIs may cause blunted affect, emotional numbness, or lack of expression. Patients may find this side effect distressing, as it affects social relationships and emotions. Before reducing the dosage, consider the muted effect. Changing medications with a reduced risk of emotional flatness may be beneficial if the current medication is inadequate. Aripiprazole and lurasidone had better effects than high-dose risperidone or olanzapine. Switching from SSRIs to bupropion or vortioxetine may restore emotional involvement. Dopamine-enhancing agents like aripiprazole or bupropion may reduce this effect. Adjusting therapy must examine whether the patient's core mental problems are well-controlled and emotional flatness.

Agranulocytosis

Agranulocytosis, a life-threatening white blood cell decrease, is most often related to clozapine but may also occur with carbamazepine. This condition needs close monitoring and raises the risk of serious infections. Immediately stop the offending agent if agranulocytosis occurs. Clozapine needs blood monitoring, and a severe neutrophil count decline warrants halting therapy. If antipsychotic medication is needed, moving to olanzapine or quetiapine may be acceptable (Dragoi et al., 2020). In rare circumstances, rechallenging under hematology monitoring may be considered for individuals who respond to clozapine. The severity of neutropenia and the clinical response to other therapies determine whether to discontinue or switch therapies.

Conclusion

In psychopharmacology, side effects must be weighed against the risks and benefits of treatment. While quitting a medicine may reduce side effects, it may increase mental problems. Often, a lower-risk option is preferable, but effectiveness must still be maintained. While maintaining the primary drug's effectiveness, supplementary therapies may help alleviate symptoms. Patient preferences and treatment objectives should be incorporated into collaborative decision-making to enhance adherence and overall well-being.

References

D’Souza, R. S., & Hooten, W. M. (2023). Extrapyramidal symptoms (EPS). Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534115/

Dragoi, A. M., Radulescu, I., Năsui, B. A., Pop, A. L., Varlas, V. N., & Trifu, S. (2020). Clozapine: An updated overview of pharmacogenetic biomarkers, risks, and safety—particularities in the context of COVID-19. Brain Sciences, 10(11), 840. https://doi.org/10.3390/brainsci10110840

Factor, S. A. (2020). Management of tardive syndrome: Medications and surgical treatments. Neurotherapeutics, 17(4), 1694–1712. https://doi.org/10.1007/s13311-020-00898-3

Lipman, K., Betterly, H., & Botros, M. (2024). Improvement in selective serotonin reuptake inhibitor-associated sexual dysfunction with buspirone: Examining the evidence. Cureus. https://doi.org/10.7759/cureus.57981

Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., Hahn, M. K., & Agarwal, S. M. (2023). Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. Therapeutic Advances in Psychopharmacology, 13, 204512532311651-204512532311651. https://doi.org/10.1177/20451253231165169